{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:23:55Z","timestamp":1792783435533,"version":"4.5.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Johnson & Johnson"},{"name":"Legend Biotech USA Inc.","id":[{"id":"https:\/\/ror.org\/04zawcj85","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"DOI":"10.1007\/s12325-026-03737-7","type":"journal-article","created":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T17:31:01Z","timestamp":1787160661000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["BRIDGE-2M: Optimizing Bridging Therapy Prior to CAR-T Therapy in Multiple Myeloma: A Modified Double-Blind Delphi Panel of US Physicians"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3781-5441","authenticated-orcid":false,"given":"Rahul","family":"Banerjee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamza","family":"Hashmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Preet M.","family":"Chaudhary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shebli","family":"Atrash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabyasachi","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd","family":"Bixby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"De Wiest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Perciavalle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David H.","family":"Vesole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Forat","family":"Lutfi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waqas","family":"Jehangir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gurbakhash","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adeel M.","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahma","family":"Warsame","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashwathi Puravankara","family":"Menon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A.","family":"Price","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guru Subramanian","family":"Guru Murthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danai","family":"Dima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian J.","family":"Carney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaina P.","family":"Qureshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saurabh","family":"Chhabra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,19]]},"reference":[{"issue":"5","key":"3737_CR1","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1038\/s41417-024-00750-2","volume":"31","author":"M Sheykhhasan","year":"2024","unstructured":"Sheykhhasan M, Ahmadieh-Yazdi A, Vicidomini R, et al. CAR T therapies in multiple myeloma: unleashing the future. Cancer Gene Ther. 2024;31(5):667\u201386.","journal-title":"Cancer Gene Ther"},{"issue":"1","key":"3737_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01191-8","volume":"14","author":"D Swan","year":"2024","unstructured":"Swan D, Madduri D, Hocking J. CAR-T\u00a0cell therapy in multiple myeloma: current status and future challenges. Blood Cancer J. 2024;14(1):206.","journal-title":"Blood Cancer J"},{"issue":"8","key":"3737_CR3","doi-asserted-by":"publisher","first-page":"2420","DOI":"10.3324\/haematol.2023.283058","volume":"109","author":"M Engelhardt","year":"2024","unstructured":"Engelhardt M, Kortum KM, Goldschmidt H, et al. Functional cure and long-term survival in multiple myeloma: how to challenge the previously impossible. Haematologica. 2024;109(8):2420\u201335.","journal-title":"Haematologica"},{"issue":"14","key":"3737_CR4","doi-asserted-by":"publisher","first-page":"2865","DOI":"10.1158\/1078-0432.CCR-24-0378","volume":"30","author":"K Natrajan","year":"2024","unstructured":"Natrajan K, Kaushal M, George B, et al. FDA approval summary: ciltacabtagene autoleucel for relapsed or refractory multiple myeloma. Clin Cancer Res. 2024;30(14):2865\u201371.","journal-title":"Clin Cancer Res"},{"key":"3737_CR5","unstructured":"US Food and Drug Administration. FDA approves idecabtagene vicleucel for multiple myeloma, March 26, 2021. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-idecabtagene-vicleucel-multiple-myeloma. Accessed 16 Apr, 2026."},{"issue":"Supplement 1","key":"3737_CR6","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.1182\/blood-2025-2799","volume":"146","author":"JY Tan","year":"2025","unstructured":"Tan JY, Vignarajah A, Atiqah N, et al. Real-world comparison of CAR T-cell therapy versus bispecific antibodies in relapsed or refractory multiple myeloma. Blood. 2025;146(Supplement 1):2799\u20132799.","journal-title":"Blood"},{"issue":"1","key":"3737_CR7","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1182\/blood.2024025945","volume":"145","author":"S Sidana","year":"2025","unstructured":"Sidana S, Patel KK, Peres LC, et al. Safety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed\/refractory multiple myeloma. Blood. 2025;145(1):85\u201397.","journal-title":"Blood"},{"issue":"11","key":"3737_CR8","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","volume":"388","author":"P Rodriguez-Otero","year":"2023","unstructured":"Rodriguez-Otero P, Ailawadhi S, Arnulf B, et al. Ide-cel or standard regimens in relapsed and refractory multiple myeloma. N Engl J Med. 2023;388(11):1002\u201314.","journal-title":"N Engl J Med"},{"issue":"4","key":"3737_CR9","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1056\/NEJMoa2303379","volume":"389","author":"J San-Miguel","year":"2023","unstructured":"San-Miguel J, Dhakal B, Yong K, et al. Cilta-cel or standard care in lenalidomide-refractory multiple myeloma. N Engl J Med. 2023;389(4):335\u201347.","journal-title":"N Engl J Med"},{"issue":"2","key":"3737_CR10","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.clml.2025.08.005","volume":"26","author":"S Ailawadhi","year":"2026","unstructured":"Ailawadhi S, Anderson LD Jr., Dhakal B, et al. Optimizing selection of bridging therapies prior to CAR-T therapy administration for multiple myeloma: clinical pearls from an expert roundtable. Clin Lymphoma Myeloma Leuk. 2026;26(2):85\u201393.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"3737_CR11","doi-asserted-by":"publisher","unstructured":"Hwa YL, Doss D, Mangan PA, et al. Understanding the role and clinical management of bridging therapy during CAR T-cell therapy for relapsed or refractory multiple myeloma. J Adv Pract Oncol. 2025;1\u20139. https:\/\/doi.org\/10.6004\/jadpro.2025.16.7.25. Accessed 23 Apr, 2026.","DOI":"10.6004\/jadpro.2025.16.7.25"},{"issue":"3","key":"3737_CR12","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_432204","volume":"44","author":"M Mohan","year":"2024","unstructured":"Mohan M, Van Oekelen O, Akhtar OS, et al. Charting the course: sequencing immunotherapy for multiple myeloma. Am Soc Clin Oncol Educ Book. 2024;44(3):e432204.","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"Supplement 1","key":"3737_CR13","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1182\/blood-2025-2215","volume":"146","author":"B Dhakal","year":"2025","unstructured":"Dhakal B, Iida S, Sidiqi MH, et al. Effectiveness of bridging therapy corresponds to improved outcomes after ciltacabtagene autoleucel: phase\u00a03 CARTITUDE-4 study of patients with relapsed, lenalidomide-refractory multiple myeloma. Blood. 2025;146(Supplement 1):2215\u20132215.","journal-title":"Blood"},{"issue":"Supplement 1","key":"3737_CR14","doi-asserted-by":"publisher","first-page":"2214","DOI":"10.1182\/blood-2025-2214","volume":"146","author":"D Hansen","year":"2025","unstructured":"Hansen D, Reid B, Grajales-Cruz A, et al. Bridging therapy response and low pre-lymphodepletion plasma cell burden are associated with improved safety and efficacy outcomes of ciltacabtagene autoleucel in multiple myeloma. Blood. 2025;146(Supplement 1):2214\u20132214.","journal-title":"Blood"},{"issue":"2, Supplement","key":"3737_CR15","doi-asserted-by":"publisher","first-page":"S234","DOI":"10.1016\/j.jtct.2025.01.357","volume":"31","author":"KJC Lim","year":"2025","unstructured":"Lim KJC, Chhabra S, Corraes ADMS, et al. Risk factors for immune effector cell-associated enterocolitis (IEC-colitis) in patients with relapsed myeloma treated with ciltacabtagene autoleucel (cilta-cel). Transplant Cell Ther. 2025;31(2, Supplement):S234\u20135.","journal-title":"Transplant Cell Ther"},{"key":"3737_CR16","doi-asserted-by":"crossref","unstructured":"Gagelmann N, Merz M, Baaij LGA, et al. Bridging therapy before CAR-T for multiple myeloma: a survey from the CMWP and CTIWP of the EBMT. Bone Marrow Transpl. 2026;61(5):642\u20134.","DOI":"10.1038\/s41409-026-02816-1"},{"key":"3737_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-026-02905-1","author":"L Rasche","year":"2026","unstructured":"Rasche L, Krauth MT, Agis H, et al. Experiences and expert panel consensus on bridging therapy before anti-BCMA CAR-T\u00a0cell therapy in multiple myeloma. Bone Marrow Transpl. 2026. https:\/\/doi.org\/10.1038\/s41409-026-02905-1.","journal-title":"Bone Marrow Transpl"},{"key":"3737_CR18","unstructured":"US Food and Drug Administration. TALVEY\u2122 Highlights of Prescribing Information August 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/761342s000lbl.pdf. Accessed 23 Apr, 2026."},{"issue":"17","key":"3737_CR19","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1182\/blood.2025029773","volume":"146","author":"B Dhakal","year":"2025","unstructured":"Dhakal B, Akhtar OS, Fandrei D, et al. Sequential targeting in multiple myeloma: talquetamab, a GPRC5D bispecific antibody, as a bridge to BCMA CAR-T therapy. Blood. 2025;146(17):2063\u201372.","journal-title":"Blood"},{"issue":"11","key":"3737_CR20","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1080\/14712598.2025.2595122","volume":"25","author":"DC Moore","year":"2025","unstructured":"Moore DC, Elsey G, McElwee J, et al. Talquetamab for the treatment of relapsed\/refractory multiple myeloma: a review of efficacy, safety, and real-world evidence. Expert Opin Biol Ther. 2025;25(11):1233\u201340.","journal-title":"Expert Opin Biol Ther"},{"issue":"8","key":"3737_CR21","doi-asserted-by":"publisher","first-page":"e374","DOI":"10.1016\/S1470-2045(24)00094-9","volume":"25","author":"Y Lin","year":"2024","unstructured":"Lin Y, Qiu L, Usmani S, et al. Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee. Lancet Oncol. 2024;25(8):e374\u201387.","journal-title":"Lancet Oncol"},{"issue":"3","key":"3737_CR22","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/s41375-024-02482-6","volume":"39","author":"LJ Costa","year":"2025","unstructured":"Costa LJ, Banerjee R, Mian H, et al. International Myeloma Working Group immunotherapy committee recommendation on sequencing immunotherapy for treatment of multiple myeloma. Leukemia. 2025;39(3):543\u201354.","journal-title":"Leukemia"},{"issue":"7","key":"3737_CR23","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000032829","volume":"102","author":"Z Shang","year":"2023","unstructured":"Shang Z. Use of Delphi in health sciences research: a narrative review. Medicine (Baltimore). 2023;102(7):e32829.","journal-title":"Medicine (Baltimore)"},{"issue":"8","key":"3737_CR24","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1177\/0269216317690685","volume":"31","author":"S Junger","year":"2017","unstructured":"Junger S, Payne SA, Brine J, et al. Guidance on Conducting and REporting DElphi Studies (CREDES) in palliative care: recommendations based on a methodological systematic review. Palliat Med. 2017;31(8):684\u2013706.","journal-title":"Palliat Med"},{"issue":"1","key":"3737_CR25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1004326","volume":"21","author":"WT Gattrell","year":"2024","unstructured":"Gattrell WT, Logullo P, van Zuuren EJ, et al. ACCORD (ACcurate COnsensus Reporting Document): a reporting guideline for consensus methods in biomedicine developed via a modified Delphi. PLoS Med. 2024;21(1):e1004326.","journal-title":"PLoS Med"},{"key":"3737_CR26","unstructured":"Fitch K, Bernstein SJ, Aguilar MD, et al. The RAND\/UCLA appropriateness method user's manual. Santa Monica: RAND; 2001."},{"issue":"6","key":"3737_CR27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0020476","volume":"6","author":"R Boulkedid","year":"2011","unstructured":"Boulkedid R, Abdoul H, Loustau M, et al. Using and reporting the Delphi method for selecting healthcare quality indicators: a systematic review. PLoS ONE. 2011;6(6):e20476.","journal-title":"PLoS ONE"},{"issue":"1","key":"3737_CR28","doi-asserted-by":"publisher","DOI":"10.5688\/ajpe7120","volume":"84","author":"JL Johnson","year":"2020","unstructured":"Johnson JL, Adkins D, Chauvin S. A review of the quality indicators of rigor in qualitative research. Am J Pharm Educ. 2020;84(1):7120.","journal-title":"Am J Pharm Educ"},{"issue":"15","key":"3737_CR29","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1182\/blood.2024024965","volume":"145","author":"CL Freeman","year":"2025","unstructured":"Freeman CL, Noble J, Menges M, et al. Tumor burden quantified by soluble B-cell maturation antigen and metabolic tumor volume determines myeloma CAR-T outcomes. Blood. 2025;145(15):1645\u201357.","journal-title":"Blood"},{"issue":"8","key":"3737_CR30","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar S, Paiva B, Anderson KC, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17(8):e328\u201346.","journal-title":"Lancet Oncol"},{"issue":"1","key":"3737_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-025-02129-7","volume":"10","author":"R Nussinov","year":"2025","unstructured":"Nussinov R, Yavuz BR, Jang H. Molecular principles underlying aggressive cancers. Signal Transduct Target Ther. 2025;10(1):42.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"3737_CR32","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1182\/hematology.2022000347","volume":"2022","author":"TM Schmidt","year":"2022","unstructured":"Schmidt TM. High or low? Assessing disease risk in multiple myeloma. Hematol Am Soc Hematol Educ Program. 2022;2022(1):349\u201355.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"3737_CR33","doi-asserted-by":"crossref","unstructured":"Chen YJ, De AP, Cong Z, et al. Multiple myeloma: Demographic and comorbidity characteristics of newly diagnosed multiple myeloma patients in the United States: A real world data analysis. Blood. 2014;1301.","DOI":"10.1182\/blood.V124.21.1301.1301"},{"issue":"1","key":"3737_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-00993-0","volume":"14","author":"A Afrough","year":"2024","unstructured":"Afrough A, Hashmi H, Hansen DK, et al. Real-world impact of bridging therapy on outcomes of ide-cel for myeloma in the U.S. Myeloma Immunotherapy Consortium. Blood Cancer J. 2024;14(1):63.","journal-title":"Blood Cancer J"},{"key":"3737_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2026.112262","volume":"195","author":"I Skrinjar","year":"2026","unstructured":"Skrinjar I, Vucic K, Puljak L. Sample size and consensus methods used in Delphi studies are heterogeneous: meta-research study. J Clin Epidemiol. 2026;195:112262.","journal-title":"J Clin Epidemiol"},{"issue":"Supplement 1","key":"3737_CR36","doi-asserted-by":"publisher","first-page":"4079","DOI":"10.1182\/blood-2025-4079","volume":"146","author":"CL Freeman","year":"2025","unstructured":"Freeman CL, Larson S, Nadeem O, et al. Trial in progress: QUINTESSENTIAL\u2014a phase\u00a02 study of arlocabtagene autoleucel (arlo-cel) in patients with relapsed\/refractory multiple myeloma (RRMM). Blood. 2025;146(Supplement 1):4079\u20134079.","journal-title":"Blood"},{"issue":"16_suppl","key":"3737_CR37","doi-asserted-by":"publisher","first-page":"TPS7564","DOI":"10.1200\/JCO.2025.43.16_suppl.TPS7564","volume":"43","author":"R Popat","year":"2025","unstructured":"Popat R, Larson SM, Yanovsky AV, et al. QUINTESSENTIAL-2: A phase\u00a03 study comparing efficacy and safety of arlocabtagene autoleucel (arlo-cel) versus standard regimens in adult patients with relapsed or refractory multiple myeloma (RRMM) refractory to lenalidomide. J Clin Oncol. 2025;43(16_suppl):TPS7564\u2013TPS7564.","journal-title":"J Clin Oncol"},{"issue":"16","key":"3737_CR38","doi-asserted-by":"publisher","first-page":"4151","DOI":"10.1182\/bloodadvances.2024015732","volume":"9","author":"JH Frenking","year":"2025","unstructured":"Frenking JH, Zhou X, Rejeski K, et al. Bridging intensity is associated with impaired hematopoietic recovery after BCMA CAR-T therapy for multiple myeloma. Blood Adv. 2025;9(16):4151\u201366.","journal-title":"Blood Adv"},{"issue":"Supplement 1","key":"3737_CR39","doi-asserted-by":"publisher","first-page":"4586","DOI":"10.1182\/blood-2025-4586","volume":"146","author":"M Rana","year":"2025","unstructured":"Rana M, Jensen A, Velayati A, et al. Non-response to bridging therapy prior to CAR-T is associated with increased toxicity and adverse outcomes in relapsed\/refractory multiple myeloma (RRMM). Blood. 2025;146(Supplement 1):4586\u20134586.","journal-title":"Blood"},{"key":"3737_CR40","unstructured":"Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Multiple Myeloma. V.5.2026 \u00a9 National Comprehensive Cancer Network, Inc. 2026. All rights reserved. Accessed April 23, 2026. Available from: To view the most recent and complete version of the guideline, go online to NCCN.org."},{"issue":"25","key":"3737_CR41","doi-asserted-by":"publisher","first-page":"2766","DOI":"10.1200\/JCO-25-00760","volume":"43","author":"S Jagannath","year":"2025","unstructured":"Jagannath S, Martin TG, Lin Y, et al. Long-term (\u22655-year) remission and survival after treatment with ciltacabtagene autoleucel in CARTITUDE-1 patients with relapsed\/refractory multiple myeloma. J Clin Oncol. 2025;43(25):2766\u201371.","journal-title":"J Clin Oncol"},{"key":"3737_CR42","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-026-03554-y","author":"S Ailawadhi","year":"2026","unstructured":"Ailawadhi S, Hansen DK, Dhakal B, et al. FREEDOMM: fifth-line or later real-world evaluation of efficacy and disease outcomes in multiple myeloma with ciltacabtagene autoleucel: treatment-free interval and overall survival in the USA. Adv Ther. 2026. https:\/\/doi.org\/10.1007\/s12325-026-03554-y.","journal-title":"Adv Ther"},{"issue":"2","key":"3737_CR43","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.71457","volume":"15","author":"H Warnakulasuriya","year":"2026","unstructured":"Warnakulasuriya H, Tiwari R. Racial and socioeconomic healthcare disparities in access to chimeric antigen receptor T (CAR-T) cell therapy for blood cancers. Cancer Med. 2026;15(2):e71457.","journal-title":"Cancer Med"}],"updated-by":[{"DOI":"10.1007\/s12325-026-03794-y","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000}}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03737-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03737-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03737-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T03:54:15Z","timestamp":1790654055000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-026-03737-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,19]]},"references-count":43,"alternative-id":["3737"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03737-7","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,19]]},"assertion":[{"value":"1 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised due to update in author name.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2026","order":8,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":9,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s12325-026-03794-y","URL":"https:\/\/doi.org\/10.1007\/s12325-026-03794-y","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Rahul Banerjee has received honoraria from AbbVie, Adaptive Biotech, Arcellx, Bristol Myers Squibb, Caribou Biosciences, Genentech, Gilead Sciences, GSK, Johnson & Johnson, Karyopharm, Legend Biotech USA Inc, Pfizer, Sanofi, and SparkCures; and has received research funding from AbbVie, Bristol Myers Squibb, Gilead Sciences, Johnson & Johnson, Karyopharm, Novartis, Pack Health, Prothena, and Sanofi. Hamza Hashmi has served on advisory boards for Johnson & Johnson and Legend Biotech USA Inc. Preet M. Chaudhary is a founder of Angeles Therapeutics, Inc., a private biotechnology company, and holds equity in Angeles Therapeutics and Sana Biotechnology; has received consultancy fees from Autolus Therapeutics and Pfizer; and has intellectual property related to cell therapies. Shebli Atrash has received honoraria from Sanofi, Johnson & Johnson, and GSK; has received consultancy fees from Sanofi and Pfizer; and has received research funding from GSK. Kimberly Green has served on advisory boards and received consultancy fees from Johnson & Johnson and Sanofi; and has received research funding from Johnson & Johnson, AbbVie, Incyte, and Nexcella. Sabyasachi Ghosh, Todd Bixby, Denise De Wiest, and Zaina P. Qureshi are employees of Johnson & Johnson and own stock\/stock options of Johnson & Johnson. Matthew Perciavalle is an employee of Legend Biotech USA Inc and owns stock\/stock options of Legend Biotech. David H. Vesole has served on speaker bureaus for Johnson & Johnson and Karyopharm. Forat Lutfi has served on an advisory board for Bristol Myers Squibb. Waqas Jehangir has served on an advisory board for Geron Pharma. Gurbakhash Kaur has received consultancy fees and honoraria from Kite Pharma, Arcellx, Bristol Myers Squibb, Karyopharm, and Johnson & Johnson; and has received research funding from Poseida, AbbVie, Kite Pharma, and Arcellx. Adeel M. Khan has received consultancy fees from Johnson & Johnson, Sanofi, and Pfizer; and has received research funding from Johnson & Johnson, Sanofi, and AbbVie. Ashwathi Puravankara Menon and Mark A. Price are employees of RTI Health Solutions, a consulting company that has provided paid consulting services to Johnson & Johnson, which funded the development and conduct of this study and manuscript. Guru Subramanian Guru Murthy has served on advisory boards for Bristol Myers Squibb, Syndax, Pfizer, BeiGene, Autolus, Gilead Sciences, and Kite Pharma; has served on speaker bureaus for Stemline, Rigel, and Amgen; has received consultancy fees from Amgen; and has received research funding from Zentalis Pharmaceuticals, Merck, Loxo Oncology, Eli Lilly, BeiGene, Schr\u00f6dinger, Gilead Sciences, and Kite Pharma. Danai Dima has served on advisory boards for Kite Pharma, Pfizer, Karyopharm, Caribou Biosciences, and Legend Biotech USA Inc. Brian J. Carney has served on an advisory board and received honoraria from Sanofi. Saurabh Chhabra has received honoraria from Sanofi, Sobi, Ascentage Pharma, Bristol Myers Squibb, Pfizer, AstraZeneca, and Legend Biotech USA Inc; and has received research funding from C4 Therapeutics, CARSgen, Cynata Therapeutics, Johnson & Johnson, Ascentage Pharma, AstraZeneca, Incyte, AbbVie, Simcere, Cullinan Therapeutics, and National Marrow Donor Program. Rahma Warsame has nothing to disclose.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was a non-interventional survey of physicians and did not involve human subjects as defined by applicable regulations, as no identifiable patient-level data were collected. Therefore, institutional review board (IRB) approval was not required. All participants were informed about the purpose of the research, and voluntary consent was obtained prior to participation.","order":2,"name":"Ethics","label":"Ethics Statement","group":{"name":"EthicsHeading","label":"Declarations"}}]}}